Dutch AI medical image analysis company Thirona spins out Retina division into Thirona Retina BV

|

|

Last update:

Netherlands-based Thirona, a company that provides software and image analysis services for the healthcare industry, announced that it has spun out its Retina division into Thirona Retina BV as of January 1, 2023. The development comes after the recent expansion of RetCAD, Thirona’s flagship AI solution for eye disease screening.

Founded in 2014 by scientist Eva van Rikxoort, Thirona BV is an artificial intelligence company that focuses on analysing retinal and lung images to precisely quantify anomalies associated with pulmonary and eye disorders. The high-precision analyses help in the development of solutions for screening, diagnostics, and personalised patient treatment.

Founder Eva van Rikxoort says, “To ensure business continuity and to allow our new entity to grow in a focused manner, Thirona BV will continue to support the Retina team with shared resources, where needed. We are happy to see our Retina business maturing and quickly gaining market traction.”

Thirona Retina BV: Everything you need to know

Thirona Retina will function as a separate legal company and concentrate solely on the market for eye illnesses. Thirona BV will keep focusing on AI-powered treatments for lung disorders in collaboration with pharma, med-tech, and clinical care integration companies.

Mark van Grinsven, MD of Thirona Retina BV, says, “We are convinced that this step will allow our Retina team to fully concentrate on the development of AI-powered solutions for eye diseases, to support growing patients’ needs and to intensify partnerships with our channel partners in eye care markets.”

Grinsven further adds, “The Class IIa European MDR CE certified RetCAD is already being integrated by all major fundus camera providers such as iCare, Topcon, Canon, Tomey and Nidek. More dedication will allow us to speed up the expansion to other channels and to grow our leadership position globally.”

Thirona’s flagship AI solution for eye disease screening, RetCAD, uses artificial intelligence to analyse colour fundus images for the presence of Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR) and Glaucoma. It helps eye care professionals in the early detection and grading of disorders that pose a hazard to eyesight.

RetCAD provides quantifiable clinical outcome measures by integrating deep learning and computer vision technologies plus a significant volume of graded photos from human experts. The product is available to clinical and optical markets through integration partnerships with all major fundus camera vendors and eye care solutions providers.

Topics:

Follow us:

Vishal Singh

Vishal Singh is a News Reporter and Social Media Marketing Lead at Silicon Canals. He covers developments in the European startup ecosystem and oversees the publication's social media presence. Before joining Silicon Canals, Vishal gained experience at the Indian digital media outlet Inc42, contributing to its growth with insightful content. Despite being a college dropout, his passion for writing has driven his career in journalism.

Partner eventsMore events

Current Month

02apr(apr 2)8:00 am04(apr 4)6:00 am0100 Europe 2025

Share to...